company background image
IPA logo

ImmunoPrecise Antibodies TSXV:IPA Stock Report

Last Price

CA$6.50

Market Cap

CA$162.1m

7D

-6.5%

1Y

-23.3%

Updated

27 Nov, 2022

Data

Company Financials +

ImmunoPrecise Antibodies Ltd.

TSXV:IPA Stock Report

Market Cap: CA$162.1m

This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

IPA Stock Overview

ImmunoPrecise Antibodies Ltd., together with its subsidiaries, operates as a biotherapeutic research and technology company in Canada and internationally.

IPA fundamental analysis
Snowflake Score
Valuation0/6
Future Growth0/6
Past Performance0/6
Financial Health4/6
Dividends0/6

ImmunoPrecise Antibodies Ltd. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for ImmunoPrecise Antibodies
Historical stock prices
Current Share PriceCA$6.50
52 Week HighCA$8.81
52 Week LowCA$4.52
Beta0.30
1 Month Change-3.70%
3 Month Change-16.77%
1 Year Change-23.26%
3 Year Change103.13%
5 Year Change160.00%
Change since IPO0.77%

Recent News & Updates

We Think ImmunoPrecise Antibodies (CVE:IPA) Needs To Drive Business Growth Carefully

Oct 20
We Think ImmunoPrecise Antibodies (CVE:IPA) Needs To Drive Business Growth Carefully

Recent updates

We Think ImmunoPrecise Antibodies (CVE:IPA) Needs To Drive Business Growth Carefully

Oct 20
We Think ImmunoPrecise Antibodies (CVE:IPA) Needs To Drive Business Growth Carefully

Earnings Update: ImmunoPrecise Antibodies Ltd. (CVE:IPA) Just Reported And Analysts Are Boosting Their Estimates

Dec 23
Earnings Update: ImmunoPrecise Antibodies Ltd. (CVE:IPA) Just Reported And Analysts Are Boosting Their Estimates

Is ImmunoPrecise Antibodies (CVE:IPA) Using Debt In A Risky Way?

Nov 25
Is ImmunoPrecise Antibodies (CVE:IPA) Using Debt In A Risky Way?

Shareholder Returns

IPACA Life SciencesCA Market
7D-6.5%-0.2%0.4%
1Y-23.3%4.5%9.0%

Return vs Industry: IPA exceeded the Canadian Life Sciences industry which returned -28.3% over the past year.

Return vs Market: IPA underperformed the Canadian Market which returned -1.4% over the past year.

Price Volatility

Is IPA's price volatile compared to industry and market?
IPA volatility
IPA Average Weekly Movement10.3%
Life Sciences Industry Average Movement7.4%
Market Average Movement8.5%
10% most volatile stocks in CA Market18.4%
10% least volatile stocks in CA Market3.1%

Stable Share Price: IPA's share price has been volatile over the past 3 months.

Volatility Over Time: IPA's weekly volatility (10%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
198385Jennifer Bathhttps://www.ipatherapeutics.com

ImmunoPrecise Antibodies Ltd., together with its subsidiaries, engages in antibody production and provision of related services in the United States, Canada, Europe, Australia, and internationally. The company offers a range of antibodies, enzymes, enzyme activity assays, arthritis animal products, proteins, deiminated proteins, organoid growth factors, and hybridoma products for research purposes. Its contract research organization services include custom antigen modeling, design, and manufacturing; B cell sorting, screening, and sequencing; custom, immune, and naive phage display production and screening; transgenic animals and multi-species antibody discovery; bi-specific, tri-specific, VHH, and VNAR (shark) antibody manufacturing; DNA cloning, protein and antibody downstream processing; antibody characterization on label-free biosensors and antibody engineering; transient and stable cell line generation; antibody optimization and humanization; hybridoma production with multiplexed, high-throughput screening, and clone-picking; and cryopreservation.

ImmunoPrecise Antibodies Ltd. Fundamentals Summary

How do ImmunoPrecise Antibodies's earnings and revenue compare to its market cap?
IPA fundamental statistics
Market capCA$162.08m
Earnings (TTM)-CA$22.86m
Revenue (TTM)CA$19.47m

8.3x

P/S Ratio

-7.1x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
IPA income statement (TTM)
RevenueCA$19.47m
Cost of RevenueCA$8.70m
Gross ProfitCA$10.76m
Other ExpensesCA$33.62m
Earnings-CA$22.86m

Last Reported Earnings

Jul 31, 2022

Next Earnings Date

n/a

Earnings per share (EPS)-0.92
Gross Margin55.29%
Net Profit Margin-117.44%
Debt/Equity Ratio0%

How did IPA perform over the long term?

See historical performance and comparison
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.